Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsCipla

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Sell BHEL, Godrej Industries; buy Cipla: Sandeep Wagle

      Sandeep Wagle of powermywealth.com is of the view that one can sell Bharat Heavy Electricals and Godrej Industries and buy Cipla.

    • Buy Cipla, Maruti Suzuki, Zee Entertainment: Chandan Taparia

      Chandan Taparia of Anand Rathi Securities is of the view that one can buy Cipla, Maruti Suzuki and Zee Entertainment.

    • Buy Cummins India, Cipla, JK Tyre: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com recommends buying Cummins India, Cipla and JK Tyre and Industries.

    • Cipla may test Rs 750, Bharat Forge Rs 1400: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com feels that Cipla may test Rs 750 and Bharat Forge may move to Rs 1400 in medium-term.

    • Buy Kotak Mahindra Bank above Rs 787; sell Lupin: Mitesh Thacker

      According to Mitesh Thacker of miteshthacker.com, one can buy Kotak Mahindra Bank above Rs 787 and sell Lupin.

    • Keep HDFC in portfolio: Vijay Chopra

      Vijay Chopra of enochventures.com is of the view that one may keep HDFC in portfolio.

    • Buy LIC Housing, PNB, IGL; Biocon may hit Rs 970: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com recommends buying LIC Housing Finance, Punjab National Bank and Indraprastha Gas while he feels that Biocon may hit Rs 970.

    • Buy Cipla; sell Wipro, GAIL India: Mitesh Thacker

      Mitesh Thacker of miteshthacker.com is of the view that one can buy Cipla and sell Wipro and GAIL India.

    • Here are some stock ideas from SP Tulsian

      Speaking about JustDial, SP Tulsian of sptulsian.com said, "Things are looking quite weak on the fundamentals. I continue to have my negative view on the stock and I won't be surprised to see it falling further from here on by about 20-30 percent".

    • Buy Cipla, Reliance Capital; sell TCS: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com recommends buying Cipla and Reliance Capital and advises selling Tata Consultancy Services.

    • Investment strategies: Top 5 stocks that you can focus today

      CLSA says large deal loss puts FY17 guidance of Infosys at risk after weak Q1. It may impact FY17 revenue by USD 50-100 million and FY18 revenue by USD 100-200 million. Its sya RBS deal cancellation puts FY17 revenue guidance at risk by 0.5-1 percent.

    • Buy Dr Reddy's Labs, Cipla, Biocon: Sanjiv Bhasin

      Sanjiv Bhasin of IIFL recommends buying Dr Reddy's Labs, Cipla and Biocon.

    • Buy Fortis Healthcare, Cipla; sell Siemens: Mitesh Thacker

      Mitesh Thacker of miteshthacker.com recommends buying Fortis Healthcare and Cipla and advises selling Siemens.

    • Here are a few stocks ideas from Prakash Diwan

      In an interview to CNBC-TV18, Prakash Diwan of prakashdiwan.in shared his readings and outlook on specific stocks and sectors.

    • Buy Cadila Healthcare, Cipla: Rajat Bose

      Rajat Bose of rajatkbose.com is of the view that one may buy Cadila Healthcare and Cipla.

    • Buy Hindustan Unilever, Cipla: Rahul Mohindar

      Rahul Mohindar of viratechindia.com recommends buying Hindustan Unilever for target of Rs 940-50 and Cipla for target of Rs 560.

    • Buy Lupin, Cipla, Godfrey Phillips India, Escorts: Rajat Bose

      Rajat Bose of rajatkbose.com is of the view that one can buy Lupin, Cipla, Godfrey Phillips India and Escorts.

    • Gautam Chhaochharia overweight on pharma space

      Gautam Chhaochharia, Head-India Research at UBS is overweight on pharma space.

    • Buy Aurobindo Pharma, United Spirits may test Rs 3200: Gujral

      Ashwani Gujral of ashwanigujral.com advises buying Aurobindo Pharma.

    • Buy ILandFS Transportation, Cadila Health, Cipla: Rajat Bose

      Rajat Bose of rajatkbose.com recommends buying ILandFS Transportation Networks, Cadila Healthcare, Cipla and South Indian Bank.

    • Buy Cipla 520 Call, advises VK Sharma

      VK Sharma of HDFC Securities is of the view that one can buy Cipla 520 Call and feels that UltraTech Cement is a better buy.

    • Lupin, Cipla top picks from pharma space: Manoj Murlidharan

      Manoj Murlidharan of Religare Securities is of the view that Lupin and Cipla are the top picks from pharma space.

    • Here are Sanjiv Bhasin's top trading ideas

      In an interview to CNBC-TV18, Sanjiv Bhasin of IIFL shared his reading and outlook on the market.

    • Why pharma stocks can rally in July: SP Tulsian

      In an interview with CNBC-TV18, market expert, SP Tulsian gave his stock picks and told why he has a positive stance on all pharma stocks for this coming month.

    • Brexit impact limited on pharma, US biz to offset risk: Analysts

      Brokerage houses do not see any major impact of Brexit on pharma companies' earnings. In fact they have not changed their views post Friday's event, saying companies may get impacted only by currency volatility globally. According to them, any EU impact will offset by US large exposure to the US.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347